Click here for the CME evaluation / post-test

Activity Index
Click on the icons below to access the indicated presentation type.
To save slides or MP3's: Right click on the appropriate icon and select "Save Target As"

Session I: State of the art treatment strategies for NSCLC

Cytotoxic chemotherapies and the new targeted therapies for lung cancer Thomas J. Lynch, Jr, MD
Recent advances in radiotherapy for NSCLC and the caveats to their use Walter J. Curran, Jr, MD
Molecular profiling and its use in guiding therapy options David M. Jablons, MD

Keynote Address:

The insulin-like growth factor system and its role in tumorigenesis Douglas Yee, MD

Session II: Hematologic malignancies I: Non-Hodgkin lymphomas

Therapeutic strategies to maximize survival with follicular lymphoma David G. Maloney, MD, PhD
T cell and non-B/non-T lymphomas James Armitage, MD

Session III: Meet the experts

Cancer in the liver: Standard & novel approaches to therapy Andrew X. Zhu, MD, PhD

Session IV: Genitourinary cancers

Therapeutic decisions in advanced renal cell carcinoma Gary R. Hudes, MD
Controversies in the management of early stage and locally advanced prostate cancer Robert Dreicer, MD, FACP
Update on the management of urothelial cancers Dean F. Bajorin, MD

Session V: Breast cancer

Treatment options for early stage breast cancer Harold J. Burstein, MD, PhD
New and up-and-coming therapeutic options for the optimal treatment of advanced/aggressive breast cancers Hope S. Rugo, MD
Unusual breast tumors: Recognition, evaluation and management Ruth M. O'Regan, MD

Session VI: Hematologic malignancies II: Myeloid malignancies

Managing CML in the era of targeted therapies: Clinical case studies Jorge Cortes, MD
Myelodysplastic syndromes: Emerging therapies and ongoing clinical trials David P. Steensma, MD

Session VII: Translational oncology: Pathways to future cancer therapies

Targeting mTOR and other components of the PI3K/AKT pathway Gary R. Hudes, MD
Epigenetic modifiers William Blum, MD
Anti-angiogenic therapies Hope S. Rugo, MD
New and upcoming therapies to inhibit the EGFR Thomas J. Lynch, Jr, MD

Session VIII: Hematologic malignancies III: Myelomas

Emerging agents for plasma cell disorders Kenneth C. Anderson, MD, MA
Debate: In the first line treatment of MM, the most important objective is the achievement of a complete response Pro: Robert Z. Orlowski, MD, PhD Con: Kenneth C. Anderson, MD, MA

Session IX: Gastrointestinal cancers

How I approach the management of esophageal cancer Bruce D. Minsky, MD
Debate: It is time to move beyond gemcitabine plus “drug X” trials in advanced pancreatic cancer Pro: John L. Marshall, MD Con: Axel Grothey, MD
First-, second-, and third-line therapies for metastatic colorectal cancer Axel Grothey, MD